Bristol-Myers Squibb Company (BMY) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 12, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Bristol-Myers Squibb Company (BMY), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Bristol-Myers Squibb Company, analysts forecast revenue falling from $47.99B in 2025 to $37.09B in 2030; the average estimate for 2030 earnings per share is $4.93; with published estimates ranging from $4.72 to $5.14; 23 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Bristol-Myers Squibb Company (BMY) forecast — frequently asked questions
What is the analyst price target for Bristol-Myers Squibb Company?
Analysts covering Bristol-Myers Squibb Company (BMY) have a consensus price target of $66.08, 4.8% above the current price of $63.04. Published targets range from $41.00 to $78.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Bristol-Myers Squibb Company's earnings?
The average analyst estimate for Bristol-Myers Squibb Company (BMY) earnings per share in 2030 is 4.93, with individual estimates between 4.72 and 5.14.
How much revenue is Bristol-Myers Squibb Company expected to make?
Analysts forecast Bristol-Myers Squibb Company (BMY) revenue of $37.09B in 2030, based on 11 published estimates.
How many analysts cover BMY?
23 analysts contribute estimates for Bristol-Myers Squibb Company (BMY). Thin coverage makes an average less reliable.
Analyst forecasts for other Drug Manufacturers - General stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.